GET THE APP

Polypharmacy and Treatment Difficulties in Patients undergoi | 95651
International Research Journals
Reach Us +44 330 818 7254

Polypharmacy and Treatment Difficulties in Patients undergoing Chemotherapy

Abstract

Giulia Escobar*

Hemodialysis patients frequently experience polypharmacy. Medication-Related Problems (MRPs), expenditures, and increased hospital admissions are all linked to it. The prevalence of polypharmacy in our setting is poorly documented. The purpose of this study is to examine the predictors of polypharmacy and MRPs and their prevalence. In the outpatient hemodialysis unit, a cross-sectional study was carried out by us. Over the course of three months, a resident in pharmacy examined electronic prescribing records to identify MRPs and discussed therapeutic interventions to enhance effective therapeutic regimens. There were 83 patients included. The median age (interquartile range) was 63. IQR = 22), and the mean number of co-morbidities was 3.14 1.64. Half of the participants were male. The 95% confidence interval (CI) for polypharmacy was 96.7 percent (91.6%–99.7%). The highest MRPs were found to be medication use without a prescription, at 36% (102/280), subtherapeutic dosing, at 23% (65/280), and overdosing, at 15% (41/280). The primary factors that were used to predict an increase in the number of medications were the presence of respiratory conditions, ischemic heart disease, and comorbidities. The Saudi hemodialysis population has a high rate of polypharmacy. The identification of MRPs and the opportunities for deprescribing to optimize medication use and reduce polypharmacy in hemodialysis patients were facilitated by a review of the medications prescribed by the pharmacist.

Share this article